Recently,there has been an unprecedented interest in the topic of angiotensin converting enzyme 2(ACE2)-associated drugs administration,such as angiotensin-converting enzyme inhibitors(ACEIs)/angiotensin II type I rec...Recently,there has been an unprecedented interest in the topic of angiotensin converting enzyme 2(ACE2)-associated drugs administration,such as angiotensin-converting enzyme inhibitors(ACEIs)/angiotensin II type I receptor blockers(ARBs),in COVID-19 patients.A recent article put forward the concern that patients taking ACEIs/ARBs were under higher risk of COVID-19 infection.[1]They revealed that expression of ACE2,the receptor for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)to enter host cells,is up-regulated,thus facilitating the initial viral attachment step of SARS-CoV-2 in these patients.[2]展开更多
文摘Recently,there has been an unprecedented interest in the topic of angiotensin converting enzyme 2(ACE2)-associated drugs administration,such as angiotensin-converting enzyme inhibitors(ACEIs)/angiotensin II type I receptor blockers(ARBs),in COVID-19 patients.A recent article put forward the concern that patients taking ACEIs/ARBs were under higher risk of COVID-19 infection.[1]They revealed that expression of ACE2,the receptor for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)to enter host cells,is up-regulated,thus facilitating the initial viral attachment step of SARS-CoV-2 in these patients.[2]
